Related Experiment Video
Updated: May 11, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Mesothelin expression is a prognostic factor in cholangiocellular carcinoma
Ryohei Nomura1, Hiroaki Fujii, Masaaki Abe
11 Department of Hepatobiliary-Pancreatic Surgery and.
International Surgery
|May 25, 2013
Summary
Mesothelin expression in cholangiocellular carcinoma (CC) was evaluated. High mesothelin levels indicate poor prognosis, suggesting its use as a prognostic indicator in CC patients.
Area of Science:
- Oncology
- Cancer Biology
- Immunohistochemistry
Background:
- Mesothelin is expressed in various cancers, including mesothelioma, ovarian, and pancreatic adenocarcinomas.
- The role and clinical significance of mesothelin in cholangiocellular carcinoma (CC) remain largely uninvestigated.
Purpose of the Study:
- To investigate mesothelin expression in cholangiocellular carcinoma (CC).
- To determine the clinical significance and prognostic value of mesothelin in CC patients.
Main Methods:
- Mesothelin expression was assessed in 25 CC patient samples using a mesothelin monoclonal antibody (5B2).
- Patients were categorized based on the percentage of mesothelin-positive tumor cells (negative/focally positive vs. positive).
- Postoperative survival rates were statistically analyzed between the groups.
Main Results:
- Mesothelin immunoreactivity was detected in 32% (8 of 25) of CC patients.
- A significant difference in postoperative survival was observed between groups (P = 0.006).
- Patients with negative or focally positive mesothelin expression had longer survival than those with positive expression.
Conclusions:
- Mesothelin expression is a significant prognostic indicator in cholangiocellular carcinoma.
- Mesothelin positivity is an independent predictor of shorter postoperative survival in CC patients.
